Angiotensin-neprilysin inhibition versus enalapril in heart failure
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS: In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. RESULTS: The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P<0.001). As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P<0.001) and decreased the symptoms and physical limitations of heart failure (P=0.001). The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group. CONCLUSIONS: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“showed superior efficacy of ARNI therapy over enalapril in chronic HF patients already receiving maximally tolerated dose of a renin-angiotensin system inhibitor (RASi).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [5]
In the citing paper
“Neprilysin inhibition does not seem to add to this effect.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“Neprilysin inhibition needs to be studied further, but does not seem to enhance this effect.224”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients)”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
In the citing paper
“In clinical trials of chronic HF patients, the prevalence of T2DM was around 30%, irrespective of HF phenotype (i.e.HFrEF and HFpEF) (Table 3).31 -48”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationA Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Cited by
Items 301–400 of 1,026
ACE Inhibitor-Induced Angioedema: a Review
Kostis, W. J., Shetty, M., Chowdhury, Y. S., & Kostis, J. B. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0859-x · Cited by 191
Oxidative Stress in Ischemic Heart Disease
Kibel, A., Lukinac, A. M., Dambic, V., Juric, I., & Selthofer-Relatic, K. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/6627144 · Cited by 144
“Natriuretic peptides (NPs) via the natriuretic peptide receptor-A are known to increase intracellular cyclic guanosine monophosphate (cGMP) levels [226].”
BackgroundAutonomic Modulation for Cardiovascular Disease
Hadaya, J. E., & Ardell, J. L. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.617459 · Cited by 166
Kario, K. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.04.001 · Cited by 144
Crucial Role of miR-433 in Regulating Cardiac Fibrosis
Tao, L., Bei, Y., Chen, P., Lei, Z., Fu, S., Zhang, H., Xu, J., Che, L., Chen, X., Sluijter, J. P., et al. (2016) · Theranostics · doi:10.7150/thno.15007 · Cited by 143
C-Type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature
Moyes, A. J., & Hobbs, A. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092281 · Cited by 168
“The results from the trial showed significantly greater benefits of this combination therapy compared to standard therapy (ACEi treatment alone) [177].”
ResultLeft Ventricular Remodeling after Myocardial Infarction: From Physiopathology to Treatment
Leancă, S. A., Crișu, D., Petriş, A. O., Afrăsânie, I., Genes, A., Costache, A. D., Tesloianu, D. N., & Costache, I. I. (2022) · Life · doi:10.3390/life12081111 · Cited by 204
Kotecha, D., Manzano, L., Krum, H., Rosano, G., Holmes, J., Altman, D. G., Collins, P. D., Packer, M., Wikstrand, J., Coats, A. J. S., et al. (2016) · BMJ · doi:10.1136/bmj.i1855 · Cited by 139
Self-citationThe Primary Outcome Is Positive — Is That Good Enough?
Pocock, S. J., & Stone, G. W. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1601511 · Cited by 142
Lindholm, D. P., Lindbäck, J., Armstrong, P. W., Budaj, A., Cannon, C. P., Granger, C. B., Hagström, E., Held, C., Köenig, W., Östlund, O., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.06.030 · Cited by 149
“, by ezetimibe or proprotein convertase subtilisin/kexin type 9 inhibition) (4,5), and neprilysin inhibition (6), that may need to be applied in selected patients rather than in the broad unselected patient”
BackgroundcGMP: a unique 2nd messenger molecule – recent developments in cGMP research and development
Friebe, A., Sandner, P., & Schmidtko, A. (2019) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01779-z · Cited by 153
Patient selection in heart failure with preserved ejection fraction clinical trials
Kelly, J. P., Mentz, R. J., Mebazaa, A., Voors, A. A., Butler, J., Roessig, L., Fiuzat, M., Zannad, F., Pitt, B., O’Connor, C. M., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.043 · Cited by 139
“The PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure) trial used a cutoff of 150 and 600 pg/ml, respectively, for BNP and NT-proBNP for patients without an HF hospitalization in the previous 12 months and 100 and 400 pg/ml, respectively, for p…”
BackgroundMethodGeographic variations in the PARADIGM-HF heart failure trial
Kristensen, S. L., Martinez, F., Jhund, P. S., Arango, J. L., Bĕlohlávek, J., Boytsov, S., Cabrera, W., Gomez, E., Hagège, A. A., Huang, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw226 · Cited by 139
“Safety outcomes included hypotension, elevation of serum creatinine, hyperkalaemia, cough, and angioedema, as previously reported.(18) We also reported total number of adverse, and serious adverse events according to geographic region.”
Self-citationPolypharmacy definition and prevalence in heart failure: a systematic review
Beezer, J., AlHatrushi, M. S., Husband, A., Kurdi, A. B., & Forsyth, P. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10135-4 · Cited by 165
“New evidence beyond the addition or ACEi/ARB, BB and MRA emerged in 2010 with ivabradine [35], sacubitril/valsartan in 2014 [36] and dapagliflozin in 2019 [37].”
BackgroundKoudstaal, S., Pujades-Rodriguez, M., Denaxas, S., Gho, J. M. I. H., Shah, A. D., Yu, N., Patel, R. S., Gale, C. P., Hoes, A. W., Cleland, J. G., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.709 · Cited by 137
Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach
Egea, O. I., Gálvez‐Montón, C., Roura, S., Perea‐Gil, I., Prat‐Vidal, C., Soler‐Botija, C., & Bayés‐Genís, A. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0013-4 · Cited by 156
“Sacubitril/Valsartan (previously known as LCZ696, and marketed by Novartis under the name of Entresto), a novel combination drug, has proven to be superior to conventional angiotensin-converting-enzyme (ACE) inhibition in reducing cardiovascular deaths and HF readmissions, in a large prospective randomized clinical tr…”
BackgroundManagement of Low Blood Pressure in Ambulatory Heart Failure with Reduced Ejection Fraction Patients
Cautela, J., Tartière, J., Solal, A. C., Bellemain-Appaix, A., Théron, A., Tibi, T., Januzzi, J. L., Roubille, F., & Girerd, N. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1835 · Cited by 156
Cardiovascular disease in chronic kidney disease
Marx-Schütt, K., Cherney, D. Z. I., Jankowski, J., Matsushita, K., Nardone, M., & Marx, N. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf167 · Cited by 185
Natriuretic peptides and cardio-renal disease
Volpe, M. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.08.032 · Cited by 159
“Meanwhile, the Prospective comparison of ARNI with ACEI to Determine Impact on GlobalMortality andmorbidity in Heart Failure (PARADIGM-HF) trial is a recently reported Phase III study that assessed the effect of LCZ696 on outcomes compared with enalapril in patients with HFrEF [136].”
ResultKozhuharov, N., Goudev, A., Flores, D., Maeder, M. T., Walter, J., Shrestha, S., Gualandro, D. M., de Oliveira Junior, M. T., Sabti, Z., Müller, B., et al. (2019) · JAMA · doi:10.1001/jama.2019.18598 · Cited by 136
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction
Chandra, A., Vaduganathan, M., Lewis, E. F., Claggett, B. L., Rizkala, A. R., Wang, W., Lefkowitz, M. P., Shi, V. C., Anand, I. S., Ge, J., et al. (2019) · JACC: Heart Failure · doi:10.1016/j.jchf.2019.05.015 · Cited by 134
Self-citationRoffi, M., Patrono, C., Collet, J., Mueller, C. E., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.10.009 · Cited by 148
Packer, M., Anker, S. D., Butler, J., Filippatos, G. S., Ferreira, J. P., Pocock, S., Rocca, H. B., Janssens, S. P., Tsutsui, H., Zhang, J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa968 · Cited by 151
Self-citationLuo, N., Fonarow, G. C., Lippmann, S., Mi, X., Heidenreich, P. A., Yancy, C. W., Greiner, M. A., Hammill, B. G., Hardy, N. C., Turner, S. J., et al. (2017) · JACC Heart Failure · doi:10.1016/j.jchf.2016.12.018 · Cited by 133
Chagas Disease: Chronic Chagas Cardiomyopathy
Echavarría, N. G., Echeverría, L. E., Stewart, M. H., Gallego, C., & Saldarriaga, C. (2019) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2019.100507 · Cited by 133
Tuleta, I., & Frangogiannis, N. G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113904 · Cited by 150
Pediatric Heart Failure: A Practical Guide to Diagnosis and Management
Masarone, D., Valente, F., Rubino, M., Vastarella, R., Gravino, R., Rea, A., Russo, M. G., Pacileo, G., & Limongelli, G. (2017) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2017.01.001 · Cited by 141
Simpson, J., Jhund, P. S., Silva‐Cardoso, J., Martinez, F., Mosterd, A., Ramires, F. J. A., Rizkala, A. R., Senni, M., Squire, I. B., Gong, J., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.08.878 · Cited by 138
Self-citationMartin, N., Manoharan, K., Thomas, J., Davies, C., & Lumbers, R. T. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012721.pub2 · Cited by 135
“Neprilysin is a neutral endopeptidase that degrades a number of endogenous vasoactive peptides serving to counteract some of the effects of RAAS activation (McMurray 2014).”
BackgroundLeft Ventricular Post-Infarct Remodeling
van der Bijl, P., Abou, R., Goedemans, L., Gersh, B. J., Holmes, D. R., Marsan, N. A., Delgado, V., & Bax, J. J. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.08.014 · Cited by 138
McKie, P. M., & Burnett, J. C. J. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.001 · Cited by 159
Bozkurt, B., & Khalaf, S. Z. (2017) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-13-4-216 · Cited by 157
Díez, J. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.656 · Cited by 147
Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.027 · Cited by 177
Self-citationSpotlight on the 2024 ESC/EACTS management of atrial fibrillation guidelines: 10 novel key aspects
Rienstra, M., Tzeis, S., Bunting, K. V., Caso, V., Crijns, H. J. G. M., De Potter, T. J. R., Sanders, P., Svennberg, E., Casado-Arroyo, R., Dwight, J., et al. (2024) · Europace · doi:10.1093/europace/euae298 · Cited by 128
Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays
Ibrahim, N. E., McCarthy, C. P., Shrestha, S., Gaggin, H. K., Mukai, R., Szymonifka, J. D., Apple, F. S., Burnett, J. C. J., Iyer, S. R., & Januzzi, J. L. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.12.063 · Cited by 136
“0) I n the PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial (1), treatment with the angiotensin receptor blocker/ neprilysin inhibitor sacubitril/valsartan resulted in a 20% relative risk reduction in the primary outcome of cardiovascul…”
MethodMichos, E. D., Reddy, T. K., Gulati, M., Brewer, L. C., Bond, R. M., Velarde, G. P., Bailey, A. L., Echols, M. R., Nasser, S. A., Bays, H. E., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100250 · Cited by 126
Gill, M., Motta‐Mejia, C., Kandžija, N., Cooke, W. R., Zhang, W., Cerdeira, A. S., Bastie, C. C., Redman, C. W. G., & Vatish, M. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.12707 · Cited by 132
Bianchi, S., Aucella, F., Nicola, L. D., Genovesi, S., Paoletti, E., & Regolisti, G. (2019) · Journal of Nephrology · doi:10.1007/s40620-019-00617-y · Cited by 145
Atualização de Tópicos Emergentes da Diretriz Brasileira de Insuficiência Cardíaca – 2021
Marcondes‐Braga, F. G., Moura, L. Z., Issa, V. S., Vieira, J. L., Rohde, L. E. P., Simões, M. V., Fernandes-Silva, M. M., Rassi, S., Martins, S. M., de Albuquerque, D. C., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210367 · Cited by 245
Neprilysin Inhibitors in Heart Failure
Bozkurt, B., Nair, A. P., Misra, A., Scott, C. Z., Mahar, J. H., & Fedson, S. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2022.05.010 · Cited by 161
“Although neprilysin has a broad role across different organ systems, its cardiovascular effects have resulted in paradigm-changing therapies in HF in the last decade.(11) Exploiting the neurohormonal benefits of natriuretic peptides has been a focus in HF since the discovery of these peptides in the 1980s.”
BackgroundResultInfluentialSex and gender differences in myocarditis and dilated cardiomyopathy: An update
Fairweather, D., Beetler, D. J., Musigk, N., Heidecker, B., Lyle, M. A., Cooper, L. T., & Bruno, K. A. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1129348 · Cited by 124
Neprilysin Inhibition to Treat Heart Failure: A Tale of Science, Serendipity, and Second Chances
McMurray, J. J. V. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.250 · Cited by 132
Self-citationWhy has Positive Inotropy Failed in Chronic Heart Failure? Lessons from Prior Inotrope Trials
Ahmad, T., Miller, P. E., McCullough, M., Desai, N. R., Riello, R. J., Psotka, M. A., Böhm, M., Allen, L. A., Teerlink, J. R., Rosano, G. M. C., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1557 · Cited by 140
Jordan, J., Stinkens, R., Jax, T., Engeli, S., Blaak, E., May, M., Havekes, B., Schindler, C., Albrecht, D., Pal, P., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.455 · Cited by 123
“Sacubitril/valsartan, a novel angiotensin receptor neprilysin inhibitor, was recently approved in the United States, Europe, and many other countries to reduce the risk of cardiovascular death and hospitalizations in patients with chronic heart failure (New York Heart Association classes II–IV) and reduced ejection fr…”
BackgroundInfluence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization
Desai, A. S., Claggett, B. L., Packer, M., Zile, M. R., Rouleau, J. L., Swedberg, K. B., Shi, V. C., Lefkowitz, M. P., Starling, R. C., Teerlink, J. R., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.04.047 · Cited by 127
Self-citationRenin angiotensin aldosterone inhibition in the treatment of cardiovascular disease
Ferrario, C. M., & Mullick, A. E. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.020 · Cited by 122
Tschöpe, C., Kherad, B., Klein, O., Lipp, A., Blaschke, F., Gutterman, D. D., Burkhoff, D., Hamdani, N., Spillmann, F., & Linthout, S. V. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1349 · Cited by 135
O’Meara, E., McDonald, M., Chan, M., Ducharme, A., Ezekowitz, J. A., Giannetti, N., Grzeslo, A., Heckman, G. A., Howlett, J. G., Koshman, S. L., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.11.036 · Cited by 122
Current and future therapeutic perspective in chronic heart failure
Mascolo, A., di Mauro, G., Cappetta, D., Angelis, A. D., Torella, D., Urbanek, K., Berrino, L., Nicoletti, G. F., Capuano, A., & Rossi, F. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106035 · Cited by 150
Russo, A. M., Desai, M. Y., Do, M. M., Butler, J., Chung, M. K., Epstein, A. E., Guglin, M. E., Levy, W. C., Piccini, J. P., Bhave, N. M., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.023 · Cited by 152
Cardiac remodelling and RAS inhibition
Ferrario, C. M. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716642677 · Cited by 135
Cardiac Management of the Patient With Duchenne Muscular Dystrophy
Buddhe, S., Cripe, L. H., Friedland‐Little, J. M., Kertesz, N. J., Eghtesady, P., Finder, J. D., Hor, K. N., Judge, D. P., Kinnett, K., McNally, E. M., et al. (2018) · PEDIATRICS · doi:10.1542/peds.2018-0333i · Cited by 126
Device-based therapies for arterial hypertension
Lauder, L., Azizi, M., Kirtane, A. J., Böhm, M., & Mahfoud, F. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0364-1 · Cited by 132
Voors, A. A., Mulder, H. S., Reyes, E. B., Cowie, M., Lassus, J. P. E., Hernandez, A. F., Ezekowitz, J. A., Butler, J., O’Connor, C. M., Koglin, J., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2221 · Cited by 128
Management of Atrial Fibrillation in Patients 75 Years and Older
Volgman, A. S., Nair, G. G., Lyubarova, R., Merchant, F. M., Mason, P. K., Curtis, A. B., WENGER, N. K., Aggarwal, N. T., Kirkpatrick, J. N., & Benjamin, E. J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.10.037 · Cited by 139
Lee, M. M. Y., McMurray, J. J. V., Lorenzo-Almorós, A., Kristensen, S. L., Sattar, N. A., Jhund, P. S., & Petrie, M. C. (2018) · Heart · doi:10.1136/heartjnl-2016-310342 · Cited by 131
Self-citationDíez‐Villanueva, P., Jiménez-Méndez, C., & Alfonso, F. (2016) · 老年心脏病学杂志:英文版 · doi:10.11909/j.issn.1671-5411.2016.02.009 · Cited by 174
Okumura, N., Jhund, P. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Swedberg, K. B., Zile, M. R., Solomon, S. D., et al. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003212 · Cited by 125
“1 Sacubitril/valsartan (formerly known as LCZ 696) is a firstin-class angiotensin receptor neprilysin inhibitor shown to be superior to enalapril in patients with heart failure with reduced ejection fraction (EF).(1,2) As such, sacubitril/valsartan has been recommended as a more effective alternative to an angiotensin…”
Self-citationAlbuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review
Claudel, S. E., & Verma, A. (2025) · Circulation · doi:10.1161/circulationaha.124.071079 · Cited by 163
“144 This would seem to challenge the association between albuminuria reduction and improved CVD outcomes and suggest that the effects of ARNI are mediated by improved blood pressure and other cardiovascular inter-mediaries.”
Role and Effective Therapeutic Target of Gut Microbiota in Heart Failure
Jia, Q., Li, H., Zhou, H., Zhang, X., Zhang, A., Xie, Y., Li, Y., Lv, S., & Zhang, J. (2019) · Cardiovascular Therapeutics · doi:10.1155/2019/5164298 · Cited by 128
Palazzuoli, A., & Iacoviello, M. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10238-6 · Cited by 140
“Sacubitril/valsartan is able to further improve HFrEF prognosis when compared with enalapril [99], and it has been associated with better control of glycemic status [100] compared to enalapril.”
BackgroundCannon, J. A., Shen, L., Jhund, P. S., Kristensen, S. L., Køber, L., Chen, F., Gong, J., Lefkowitz, M. P., Rouleau, J. L., Shi, V. C., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.687 · Cited by 124
Self-citationPaediatric cardio-oncology: epidemiology, screening, prevention, and treatment
Chow, E. J., Leger, K. J., Bhatt, N. S., Mulrooney, D. A., Ross, C. J., Aggarwal, S. A., Bansal, N., Ehrhardt, M. J., Armenian, S. H., Scott, J. M., et al. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz031 · Cited by 129
“There are newer medications that have also been studied in adult heart failure patients including the combination drug sacubitril/valsartan that have shown greater survival compared to enalapril.(93) Unfortunately, patients with cardiomyopathy 0 10 20 30 40”
State of the Art Review: Brachial-Ankle PWV
Tomiyama, H., & Shiina, K. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17041 · Cited by 131
(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
Neurohumoral Activation in Heart Failure
Manolis, A. S., Manolis, T. A., & Manolis, A. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015472 · Cited by 161
“They are a group of molecules secreted in response to myocardial stretch, with pertinent effects on natriuresis, vasodilatation and curtailing fibrosis, explored for their prognostic and therapeutic uses [90,91].”
BackgroundSarwar, C. M. S., Papadimitriou, L., Pitt, B., Piña, I. L., Zannad, F. M., Anker, S. D., Gheorghiade, M., & Butler, J. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.060 · Cited by 127
“In the PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure) trial, despite renal function, potassium-based eligibility criteria, and a run-in period, approximately 15% of patients in both the LCZ696 and the enalapril arms developed hyperkalemia (…”
MethodMultifunctional Role of Chymase in Acute and Chronic Tissue Injury and Remodeling
Dell’Italia, L. J., Collawn, J. F., & Ferrario, C. M. (2018) · Circulation Research · doi:10.1161/circresaha.117.310978 · Cited by 113
“Likewise, the success of neprilysin blockade added to AT 1 receptor blockade in patients with heart failure demonstrates only a 20% benefit over a ACE inhibitorbased treatment approach.(16,17) This review will highlight the extensive evidence implicating chymase in pathobiology, with an emphasis on (1) human and anima…”
BackgroundGardner, R. S., Singh, J. P., Stancak, B., Nair, D. G., Cao, M. K., Schulze, C., Thakur, P. H., An, Q., Wehrenberg, S., Hammill, E. F., et al. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004669 · Cited by 133
Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America
Bloom, M. W., Vo, J. B., Rodgers, J. E., FERRARI, A. M., Nohria, A., Deswal, A. M., Cheng, R. K.-H., Kittleson, M. M., Upshaw, J. N., Palaskas, N. L., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.08.045 · Cited by 140
Update on heart failure management and future directions
Choi, H., Park, M., & Youn, J. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2018.428 · Cited by 126
“Therefore, most patients classified as HFmrEF have various features of HFrEF and HFpEF, rather than belonging to groups with unique characteristics.”
BackgroundInfluentialAlmufleh, A. S., Marbach, J. A., Chih, S., Stadnick, E., Davies, R. A., Liu, P. X., & Mielniczuk, L. M. (2017) · PubMed Central · Cited by 114
von Haehling, S., Arzt, M. E., Doehner, W., Edelmann, F., Evertz, R., Ebner, N., Herrmann‐Lingen, C., Garfias‐Veitl, T., Koziolek, M. J., Noutsias, M., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1838 · Cited by 126
Bakaeen, F. G., Gaudino, M. F. L., Whitman, G. R., Doenst, T., Ruel, M., Taggart, D. P., Stulak, J. M., Benedetto, U., Anyanwu, A., Chikwe, J., et al. (2021) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.04.052 · Cited by 131
“157,158 Recent strong evidence from several large RCTs of HFrEF patients without regard to diabetes status is likely to expand GDMT to include sodium-glucose cotransporter 2 inhibitors.”
BackgroundNatriuretic Peptides in Heart Failure
Maisel, A. S., Duran, J. M., & Wettersten, N. W. (2017) · Heart Failure Clinics · doi:10.1016/j.hfc.2017.08.002 · Cited by 126
Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists
Wilcox, T., De Block, C., Schwartzbard, A. Z., & Newman, J. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.056 · Cited by 112
“As previously characterized (2), heart failure (HF) is also underrecognized among T2DM patients and increases mortality (3).”
BackgroundSavarese, G., Xu, H., Trevisan, M., Dahlström, U., Rossignol, P., Pitt, B., Lund, L. H., & Carrero, J. J. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.10.003 · Cited by 113
Characteristics, Outcomes, and Treatment of Heart Failure With Improved Ejection Fraction
Park, C. S., Park, J. J., Mebazaa, A., Oh, I., Park, H. A., Cho, H., Lee, H., Kim, K. H., Yoo, B., Kang, S., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011077 · Cited by 123
Impact Analysis of Heart Failure Across European Countries: An ESC-HFA Position Paper
Rosano, G. M. C., Seferovic, P. M., Savarese, G., Spoletini, I., Lopatin, Y. M., Gustafsson, F., Bayés‐Genís, A., Jaarsma, T., Abdelhamid, M., González, A., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14076 · Cited by 132
Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation
Solomon, S. D., Claggett, B. L., Packer, M., Desai, A., Zile, M. R., Swedberg, K. B., Rouleau, J. L., Shi, V. C., Lefkowitz, M. P., & McMurray, J. J. V. (2016) · JACC Heart Failure · doi:10.1016/j.jchf.2016.05.002 · Cited by 111
Self-citationDrug discovery for chagas disease: A viewpoint
Kratz, J. M. (2019) · Acta Tropica · doi:10.1016/j.actatropica.2019.105107 · Cited by 128
Selvaraj, S., Claggett, B., Pozzi, A., McMurray, J. J. V., Jhund, P. S., Packer, M., Desai, A. S., Lewis, E. F., Vaduganathan, M., Lefkowitz, M. P., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.039920 · Cited by 111
Self-citationEdner, M., Benson, L., Dahlström, U., & Lund, L. H. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv268 · Cited by 111
“A novel combined ARB neprilysin-inhibitor (ARNi) was found to be superior to an ACEI alone and may gradually replace ACEIs in clinical practice, but similar to other HF trials, this trial also excluded patients with severe renal insufficiency.(26) Whether to test an ACEI or an ARNi vs.”
ResultMoe, G. W. P. L., Ezekowitz, J. A., O’Meara, E., Lepage, S., Howlett, J. G., Fremes, S. E., Al‐Hesayen, A., Heckman, G. A., Abrams, H. B., Ducharme, A., et al. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.10.022 · Cited by 119
“Patients in this trial and the absolute benefit were quite comparable with those in other trials that changed clinical practice, including trials of ACE inhibitors, b-blockers, and mineralocorticoid anatagonists.(92) Because of the size of the trial, the use of a gold-standard active control of high-dose enalapril and…”
MethodResultLangenickel, T., Tsubouchi, C., Ayalasomayajula, S. P., Pal, P., Valentin, M., Hinder, M., Jhee, S. S., Gevorkyan, H., & Rajman, I. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12861 · Cited by 118
Zile, M. R., Bennett, T., Hajj, S. C. E., Kueffer, F. J., Baicu, C. F., Abraham, W. T., Bourge, R. C., & Stevenson, L. W. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003594 · Cited by 114
Self-citationManagement of Heart Failure Patient with CKD
Banerjee, D., Rosano, G., & Herzog, C. A. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14180920 · Cited by 139
Bavishi, C., Messerli, F. H., Kadosh, B., Ruilope, L. M., & Kario, K. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv142 · Cited by 110
“LCZ696 showed no significant change in heart rate from baseline in any of the trials.(22,23,27,28) Ruilope et al.”
BackgroundPostinfarct Left Ventricular Remodelling: A Prevailing Cause of Heart Failure
Galli, A., & Lombardi, F. (2016) · Cardiology Research and Practice · doi:10.1155/2016/2579832 · Cited by 137
Chandra, A., Lewis, E. F., Claggett, B. L., Desai, A. S., Packer, M., Zile, M. R., Swedberg, K. B., Rouleau, J. L., Shi, V. C., Lefkowitz, M. P., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.0398 · Cited by 123
Self-citationKhariton, Y., Nassif, M. E., Thomas, L., Fonarow, G. C., Mi, X., DeVore, A. D., Duffy, C., Sharma, P. P., Albert, N. M., Patterson, J. H., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.02.002 · Cited by 108
The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure
Pugliese, N. R., Masi, S., & Taddei, S. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09855-5 · Cited by 120
Rohde, L. E. P., Chatterjee, N. A., Vaduganathan, M., Claggett, B. L., Packer, M., Desai, A. S., Zile, M. R., Rouleau, J. L., Swedberg, K. B., Lefkowitz, M. P., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.06.015 · Cited by 135
Self-citationJering, K., Claggett, B. L., Pfeffer, M. A., Granger, C. B., Køber, L., Lewis, E. F., Maggioni, A. P., Mann, D. L., McMurray, J. J. V., Rouleau, J. L., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2191 · Cited by 123
Self-citationDrug Discovery for Kinetoplastid Diseases: Future Directions
Rao, S. P. S., Barrett, M. P., Dranoff, G., Faraday, C. J., Gimpelewicz, C. R., Hailu, A., Jones, C. L., Kelly, J. M., Lazdins-Helds, J. K., Mäser, P., et al. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00298 · Cited by 107
Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan
Claggett, B., Packer, M., McMurray, J. J. V., Swedberg, K., Rouleau, J., Zile, M. R., Jhund, P., Lefkowitz, M., Shi, V., & Solomon, S. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1509753 · Cited by 108
Self-citationBiomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity
Michel, L., Rassaf, T., & Totzeck, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.08.15 · Cited by 118
“This balances maladaptive neuro-humoral mechanisms in heart failure (13,15).”
BackgroundPrognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial
Januzzi, J. L., Zannad, F. M., Anker, S. D., Butler, J., Filippatos, G. S., Pocock, S., Ferreira, J. P., Sattar, N. A., Verma, S., Vedin, O., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.046 · Cited by 118
Self-citationFocus on renal congestion in heart failure
Afşar, B., Ortíz, A., Covic, A. C., Solak, Y., Goldsmith, D. J. A., & Kanbay, M. (2015) · Clinical Kidney Journal · doi:10.1093/ckj/sfv124 · Cited by 115
“A recent trial comparing the angiotensin receptor–neprilysin inhibitor LCZ696with enalapril in HF patients with reduced ejection fraction was stopped early due to the obvious superiority of LCZ696 with respect to the primary outcome, a composite of death from cardiovascular causes or hospitalization for HF, as well as…”
Background
Metadata
- Authors
- McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., & Zile, M. R.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- Montreal Heart Institute (CA)
- Imperial College London (GB)
- Medical University of South Carolina (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-11
- Volume
- 371
- Issue
- 11
- Pages
- 993-1004
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2113698123
- Cited by
- 6,957
- References
- 30
- Citations by year
- 2026: 432 · 2025: 599 · 2024: 634 · 2023: 711 · 2022: 725 · 2021: 758 · 2020: 750 · 2019: 613 · 2018: 482 · 2017: 484 · 2016: 411 · 2015: 296 · 2014: 41
- FWCI
- 281.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Keele Research Repository (Keele University) (submittedVersion, cc-by)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- angiotensin receptor-neprilysin inhibition, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, heart failure symptoms, hypotension, angiotensin II receptor blockade, ACE inhibitors, renin-angiotensin system, heart failure prognosis, heart failure with preserved ejection fraction
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Stroke Volume, Tetrazoles, Neprilysin, Kaplan-Meier Estimate, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.